Gw Pharmaceuticals Plc Stock EBITDA

GW Pharmaceuticals Plc fundamentals help investors to digest information that contributes to GW Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GWPH Stock. The fundamental analysis module provides a way to measure GW Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GW Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GWPH EBITDA Analysis

GW Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current GW Pharmaceuticals EBITDA

    
  (39.01 M)  
Most of GW Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GW Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, GW Pharmaceuticals Plc reported earnings before interest,tax, depreciation and amortization of (39.01 Million). This is 104.45% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The ebitda for all United States stocks is 101.0% higher than that of the company.

GWPH EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GW Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GW Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GW Pharmaceuticals by comparing valuation metrics of similar companies.
GW Pharmaceuticals is currently under evaluation in ebitda category among related companies.

GWPH Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance